NASDAQ:ARTC - 438426 Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New 438426 Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARTC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
This price target is based on 1 analysts offering 12 month price targets for 438426 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Buy
The current consensus among 1 polled investment analysts is to buy stock in 438426.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2020Raymond JamesInitiated CoverageOutperformN/A
i
1/22/2018Chardan CapitalInitiated CoverageBuyLow
i
(Data available from 3/6/2016 forward)
438426 logo
ArthroCare Corporation (ArthroCare) is a medical device company. ArthroCare develops and manufactures surgical devices, instruments, and implants. Its devices enable surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its Coblation technology. This technology dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology, including its OPUS line of fixation products, as well as re-usable surgical instruments. ArthroCare’s two core product consists of sports medicine and ear, nose, and throat (ENT), as well as other areas, such as spine, wound care, urology and gynecology. It’s Sports Medicine, ENT and other products are marketed and sold through two principal geographic distribution channels: Americas (North and South America) and International (all other geographies). In May 2014, Smith & Nephew PLC acquired the Company.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.61
$1.48
$1.76

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 438426?

The following Wall Street analysts have issued reports on 438426 in the last year: Raymond James.
View the latest analyst ratings for ARTC.

What is the current price target for 438426?

0 Wall Street analysts have set twelve-month price targets for 438426 in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for 438426 in the next year.
View the latest price targets for ARTC.

What is the current consensus analyst rating for 438426?

438426 currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARTC will outperform the market and that investors should add to their positions of 438426.
View the latest ratings for ARTC.

What other companies compete with 438426?

How do I contact 438426's investor relations team?

438426's physical mailing address is 7000 W William Cannon Dr, AUSTIN, TX 78735-8509, United States. The medical device company's listed phone number is +1-512-3913900. The official website for 438426 is www.arthrocare.com.